SG11202109662YA - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer

Info

Publication number
SG11202109662YA
SG11202109662YA SG11202109662YA SG11202109662YA SG 11202109662Y A SG11202109662Y A SG 11202109662YA SG 11202109662Y A SG11202109662Y A SG 11202109662YA SG 11202109662Y A SG11202109662Y A SG 11202109662YA
Authority
SG
Singapore
Prior art keywords
compound
cancer
alkyl
hydrogen
glucose
Prior art date
Application number
Other languages
English (en)
Inventor
David A Nathanson
Michael E Jung
Jonathan Tsang
Lorenz Urner
Peter M Clark
Timothy F Cloughesy
Gyudong Kim
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11202109662YA publication Critical patent/SG11202109662YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202109662Y 2019-03-15 2020-03-13 Compositions and methods for treating cancer SG11202109662YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819322P 2019-03-15 2019-03-15
US201962904241P 2019-09-23 2019-09-23
PCT/US2020/022743 WO2020190765A2 (en) 2019-03-15 2020-03-13 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
SG11202109662YA true SG11202109662YA (en) 2021-10-28

Family

ID=72521289

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109662Y SG11202109662YA (en) 2019-03-15 2020-03-13 Compositions and methods for treating cancer

Country Status (17)

Country Link
US (3) US11377451B2 (cg-RX-API-DMAC7.html)
EP (1) EP3938354A4 (cg-RX-API-DMAC7.html)
JP (2) JP7474269B2 (cg-RX-API-DMAC7.html)
KR (1) KR102809395B1 (cg-RX-API-DMAC7.html)
CN (2) CN115215808B (cg-RX-API-DMAC7.html)
AU (1) AU2020241703B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021018295A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133688A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002409A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021013496A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210498A (cg-RX-API-DMAC7.html)
IL (1) IL286350A (cg-RX-API-DMAC7.html)
MX (1) MX2021011272A (cg-RX-API-DMAC7.html)
PH (1) PH12021552208A1 (cg-RX-API-DMAC7.html)
SA (1) SA521430328B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109662YA (cg-RX-API-DMAC7.html)
WO (1) WO2020190765A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240017986A (ko) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
KR102809395B1 (ko) 2019-03-15 2025-05-16 더 리전트 오브 더 유니버시티 오브 캘리포니아 암을 치료하기 위한 조성물 및 방법
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2022061201A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022155311A1 (en) * 2021-01-14 2022-07-21 The Regents Of The University Of California Methods and systems for analysis of drug target engagement and treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
US20240165132A1 (en) * 2021-05-12 2024-05-23 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
CA3233057A1 (en) * 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors
US20260108524A1 (en) * 2022-10-14 2026-04-23 The Regents Of The University Of California Egfr inhibitors for treating lung cancer
WO2024102177A1 (en) * 2022-11-08 2024-05-16 The Regents Of The University Of California Combination therapies for the treatment of brain cancer
AU2024388187A1 (en) * 2023-11-27 2026-06-18 Katmai Pharmaceuticals, Inc. Compositions and methods for treating cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법
CN1854130B (zh) 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
WO2008046242A1 (fr) 2006-10-16 2008-04-24 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
ITPD20110091A1 (it) 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
CA3081443A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
WO2016123706A1 (en) * 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Novel fluorinated derivatives as egfr inhibitors useful for treating cancers
CN105017163A (zh) 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
US10473255B2 (en) 2015-12-29 2019-11-12 Ge-Hitachi Nuclear Energy Americas Llc Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device
CA3008312A1 (en) 2016-01-06 2017-07-13 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
CN106432202B (zh) 2016-09-22 2019-04-02 郑州大学第一附属医院 喹唑啉类衍生物及其应用
KR20240017986A (ko) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
KR102809395B1 (ko) * 2019-03-15 2025-05-16 더 리전트 오브 더 유니버시티 오브 캘리포니아 암을 치료하기 위한 조성물 및 방법
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061201A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
CA3233057A1 (en) * 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
US20230115366A1 (en) 2023-04-13
CN115215808A (zh) 2022-10-21
KR20210151820A (ko) 2021-12-14
EP3938354A4 (en) 2022-12-28
IL286350A (en) 2021-10-31
BR112021018295A2 (pt) 2021-11-23
JP7789832B2 (ja) 2025-12-22
PH12021552208A1 (en) 2022-05-30
CR20210498A (es) 2022-01-11
CL2021002409A1 (es) 2022-06-17
US11377451B2 (en) 2022-07-05
AU2020241703B2 (en) 2026-02-05
JP7474269B2 (ja) 2024-04-24
JP2024102094A (ja) 2024-07-30
MX2021011272A (es) 2021-10-01
US20250145634A1 (en) 2025-05-08
WO2020190765A3 (en) 2020-11-26
EP3938354A2 (en) 2022-01-19
CN115215808B (zh) 2025-04-18
SA521430328B1 (ar) 2024-03-28
WO2020190765A2 (en) 2020-09-24
AU2020241703A1 (en) 2021-10-14
CN113811528A (zh) 2021-12-17
CO2021013496A2 (es) 2022-01-17
KR102809395B1 (ko) 2025-05-16
CA3133688A1 (en) 2020-09-24
US20220064177A1 (en) 2022-03-03
JP2022526266A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
US11377451B2 (en) Compositions and methods for treating cancer
AU2023282187B2 (en) Compositions and methods for treating cancer
US20220062291A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) with reduced inhibitory activity targeted to the dopamine d2 receptor and accompanying toxicity
US9205091B2 (en) Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
US9040585B2 (en) Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (PIP3) and uses thereof
EP3125901A1 (en) New derivatives of cephalosporin for treating cancer
Zhang et al. Anti-cancer effects of bis-oxidized thiopyran derivatives on non-small cell lung cancer: rational design, synthesis, and activity evaluation
JP7244511B2 (ja) Ly6Kを阻害する化合物およびそれらを使用する方法
US20250082765A1 (en) Molecules as anticancer agents for targeted treatment of breast and prostate cancer
US20140045883A1 (en) Ack1 kinase inhibition to treat triple negative breast cancer
Pramanik Development of hedgehog pathway inhibitors (HPI) in treatment of cancer
KR100961688B1 (ko) 다중약물내성 암세포에 유용한 항암제
CN108976235B (zh) 一种喹唑啉酮类化合物及其用途
EA044668B1 (ru) Композиции и способы для лечения рака
HK40062377A (en) Compositions and methods for treating cancer
HK40083017A (en) Compositions and methods for treating cancer
KR20070025135A (ko) 세프트리악손을 포함하는 stat3 활성 저해 활성을가지는 조성물